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OBJECTIVE — No guidelines for A1C measurement exist for women with gestational diabe-
tes mellitus (GDM). The aim of this study was to document the rate of A1C decline in women
with GDM.
RESEARCH DESIGN AND METHODS — Women with GDM in the Santa Barbara
County Endocrine Clinic are managed with a carbohydrate-restricted diet and self-monitored
blood glucose before and 1-h postprandial. Insulin is started if the preprandial glucose concen-
tration is 90 mg/dl and/or a 1-h postprandial glucose concentration is 120 mg/dl. Capillary
A1C was tested weekly using the DCA2000 analyzer.
RESULTS — Twenty-fourwomenwithGDM(aged29.07.3years)withinitialA1C7.0%
were recruited. Baseline A1C was 8.8  1.8%. Mean A1C decline was 0.47% per week (range
0.10–1.15%); the maximum was 4.3% in 4 weeks.
CONCLUSIONS — This study documents rapid decline in A1C during pregnancy and the
utility of weekly A1C to guide therapy.
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A
1C is routinely measured approxi-
mately every 3 months in individu-
als with diabetes to assess the mean
glucose concentration. The erythrocyte
life span is 120 days (1). Thus, the
3-monthintervalbetweentestsofA1Cre-
ﬂects the mean blood glucose over the
preceding weeks to months. There are no
clear guidelines for the frequency of test-
ing A1C during pregnancy (2). In preg-
nancies complicated by type 1 or type 2
diabetes, most studies report the relation-
ship between the ﬁrst trimester A1C and
the risk of spontaneous abortion and/or
congenital malformations (3,4). The goal
fortherapyinpregestationaldiabetesisto
sustain the A1C at 6.0%, although this
level of A1C assumes that the measure-
ment is performed only once each trimes-
ter (5–9). In addition, A1C is not
recommended routinely in women with
gestational diabetes mellitus (GDM). The
life span of the erythrocyte during preg-
nancy is shortened to 90 days, and thus
the test measures the mean glucose over a
shorter time interval than in the nonpreg-
nant state (10). Hence, the rate of change
of A1C in pregnancy reﬂects the glycemic
control over the past few weeks. There-
fore, the measurement of A1C more fre-
quently during pregnancy may be used to
guide therapeutic decisions in all preg-
nancies complicated by diabetes includ-
ing GDM. The aim of this study was to
document the rate of A1C decline during
the ﬁrst 4 weeks after the initiation of
treatment in women with GDM.
RESEARCH DESIGN AND
METHODS— This was an observa-
tionalstudyofpregnantwomenattending
the Santa Barbara County Health Care
Services Obstetrics Clinic for care who
have the diagnosis of GDM (diabetes ﬁrst
diagnosed during pregnancy [2]) and
who were referred to the Prenatal Diabe-
tes/EndocrineClinicformanagement.Be-
cause of the high rates of diabetes in this
largely Latino population and because
many of the women only seek medical
attention during pregnancy, women are
screened for GDM very early in preg-
nancy. Many women found to have dia-
betes early in pregnancy undoubtedly
have preexisting type 2 diabetes, which
falls under the classiﬁcation of GDM
when ﬁrst identiﬁed during pregnancy.
Treatment consists of a carbohydrate-
restricted meal plan (11) and ﬁngerstick
blood glucose monitoring before and 1-h
after each meal (11). Insulin is initiated if
the diet does not achieve premeal glucose
concentrations 90 mg/dl and/or 1-h
postprandial glucose concentrations
120 mg/dl within 1 week of the carbo-
hydrate restriction prescription (12,13).
For simplicity in the clinic and to impress
upon the diabetic women the importance
of tight glucose control, a point of care
A1Cbyﬁngerstickisroutinelyobtainedat
every weekly visit and analyzed immedi-
ately using the DCA2000 analyzer
(14,15). The DCA A1C is a Clinical Lab-
oratory Improvement Amendments
(CLIA)-waived test with a coefﬁcient of
variation of 2.3–3.3% at a normal A1C
concentration of 5.2 and of 2.8–3.7% at
an elevated A1C concentration of 11.9%.
RESULTS— Twenty-four Latina
womenwiththediagnosisofGDMwhose
initialA1Cwas7.0%andfolloweddur-
ing the ﬁrst 1–4 weeks of treatment were
included in the analysis. The mean  SD
age was 29.0  7.3 years, A1C at enroll-
ment was 8.80  1.83, and the duration
of follow-up for this study was 3.2  1.0
weeks. Mean gestational age at diagnosis
of GDM was 12.2  7.4 weeks.
Figure 1 shows the A1C decline dur-
ing the ﬁrst 4 weeks of treatment (range
1.0–4.0 weeks) for all 24 women. The
mean decline was 0.47  0.30% per
week, and the maximum decline over the
4weekswas4.3%.Thedeclinewasgreat-
estamongwomenwiththehighestA1Cat
baseline. Among the 20 women with an
initial A1C 10.0%, the decline was
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Sansum Diabetes Research Institute, Santa Barbara, California.
Corresponding author: Lois Jovanovic ˇ, ljovanovic@sansum.org.
Received 30 July 2010 and accepted 26 September 2010. Published ahead of print at http://care.
diabetesjournals.org on 4 October 2010. DOI: 10.2337/dc10-1455.
© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
BRIEF REPORT
care.diabetesjournals.org DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 530.36  0.15% per week. After the 1st
month of decline, the A1C stabilized with
a small drop of only 0.05% per week to
the end of gestation (data not shown).
CONCLUSIONS — This study docu-
ments that a rapid decline in A1C can be
achieved during pregnancy when normo-
glycemia is vigorously instituted and
achieved and thereafter sustained for 4
weeks. Home glucose monitoring on a
regular basis is certainly the cornerstone
of management of GDM and was initiated
in the women enrolled in this study from
the beginning. However, many high glu-
cosevaluescanbemissedwiththeusualsix
or seven ﬁngersticks per day. When A1C is
measured at every weekly visit and the re-
sultiscomparedwiththewoman’sprevious
value, then the rate of change of A1C (de-
cline or rise) can be used to assess the gly-
cemic control and guide therapeutic
decisions. A randomized trial in a larger
group of women will be needed to deter-
mine whether weekly A1C measurements
will lead to an improvement in outcome.
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Figure 1—A1C (%) at enrollment and weekly
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